A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses
- PMID: 30360122
- DOI: 10.1021/acsami.8b11556
A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses
Abstract
Cervical cancer remains the second-most prevalent female malignancy around the world, leading to a great majority of cancer-related mortality that occurs mainly in developing countries. Developing an effective and low-cost vaccine against human papillomavirus (HPV) infection, especially in medically underfunded areas, is urgent. Compared with vaccines based on HPV L1 viruslike particles (VLPs) in the market, recombinant HPV L1 pentamer expressed in Escherichia coli represents a promising and potentially cost-effective vaccine for preventing HPV infection. Hybrid particles comprising a polymer core and lipid shell have shown great potential compared to conventional aluminum salts adjuvant and is urgently needed for HPV L1 pentamer vaccines. It is well-reported that particle sizes are crucial in regulating immune responses. Nevertheless, reports on the relationship between the particulate size and the resultant immune response have been in conflict, and there is no answer to how the size of particles regulates specific immune response for HPV L1 pentamer-based candidate vaccines. Here, we fabricated HPV 16 L1 pentamer-loaded poly(d,l-lactide- co-glycolide) (PLGA)/lecithin hybrid particles with uniform sizes (0.3, 1, and 3 μm) and investigated the particle size effects on antigen release, activation of lymphocytes, dendritic cells (DCs) activation and maturation, follicular helper CD4+ T (TFH) cells differentiation, and release of pro-inflammatory cytokines and chemokines. Compared with the other particle sizes, 1 μm particles induced more powerful antibody protection and yielded more persistent antibody responses, as well as more heightened anamnestic responses upon repeat vaccination. The superior immune responses might be attributed to sustainable antigen release and robust antigen uptake and transport and then further promoted a series of cascade reactions, including enhanced DCs maturation, increased lymphocytes activation, and augmented TFH cells differentiation in draining lymph nodes (DLNs). Here, a powerful and economical platform for HPV vaccine and a comprehensive understanding of particle size effect on immune responses for HPV L1 pentamer-based candidate vaccines are provided.
Keywords: adjuvant; human papillomavirus; particle; pentamer; size.
Similar articles
-
In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.Sci Rep. 2019 Oct 23;9(1):15225. doi: 10.1038/s41598-019-51679-8. Sci Rep. 2019. PMID: 31645650 Free PMC article.
-
Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.Vaccine. 2012 Jun 13;30(28):4127-34. doi: 10.1016/j.vaccine.2012.04.079. Epub 2012 May 1. Vaccine. 2012. PMID: 22561312
-
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26. J Natl Cancer Inst. 2009. PMID: 19470949 Free PMC article.
-
Developments in L2-based human papillomavirus (HPV) vaccines.Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23. Virus Res. 2017. PMID: 27889616 Free PMC article. Review.
-
Papillomavirus-like particle based vaccines: cervical cancer and beyond.Expert Opin Biol Ther. 2001 Jul;1(4):571-81. doi: 10.1517/14712598.1.4.571. Expert Opin Biol Ther. 2001. PMID: 11727495 Review.
Cited by
-
Advanced biomaterials for cancer immunotherapy.Acta Pharmacol Sin. 2020 Jul;41(7):911-927. doi: 10.1038/s41401-020-0372-z. Epub 2020 Mar 2. Acta Pharmacol Sin. 2020. PMID: 32123302 Free PMC article. Review.
-
Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.ACS Biomater Sci Eng. 2020 Feb 10;6(2):759-778. doi: 10.1021/acsbiomaterials.9b01255. Epub 2020 Jan 12. ACS Biomater Sci Eng. 2020. PMID: 33313391 Free PMC article. Review.
-
Light-activated nanomaterials for tumor immunotherapy.Front Chem. 2022 Oct 7;10:1031811. doi: 10.3389/fchem.2022.1031811. eCollection 2022. Front Chem. 2022. PMID: 36277335 Free PMC article. Review.
-
Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications.Nano Converg. 2022 Apr 28;9(1):19. doi: 10.1186/s40580-022-00310-0. Nano Converg. 2022. PMID: 35482149 Free PMC article. Review.
-
Adjuvant activity of tubeimosides by mediating the local immune microenvironment.Front Immunol. 2023 Feb 10;14:1108244. doi: 10.3389/fimmu.2023.1108244. eCollection 2023. Front Immunol. 2023. PMID: 36845089 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials